Product Description
Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free Benicar cases related to villous atrophy and other injuries. Here at Leading Justice, we can custom tailor your firm’s Benicar advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Benicar advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that isn’t eligible for the target campaign is reviewed to determine whether it qualifies for another type of claim. By using advanced approaches to target contacts specifically related to Benicar and side effects like villous atrophy, long-term diarrhea from Benicar and weight loss, Leading Justice will increase your firm’s Benicar case load. If you are interested in helping victims of alleged Benicar complications, our extensive consumer reach and direct advertising strategies at Leading Justice give you the competitive edge and confidence you need to allocate your full budget, with the knowledge that your money is being used in the best way possible.
Each law firm we work with at Leading Justice plays an important role in how we classify claims as qualified or not. Our considerable experience working with plaintiff law firms helps us recognize a great case when we see one, but we will also customize our Benicar case intake specifications to the exact criteria you are seeking. So, if your firm has certain Benicar qualifying case criteria you would like us to use, we can train our intake specialists to apply the criteria to every phone call and email they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of Benicar data with zero chance of fraud.
Benicar and Intestinal Damage Litigation
Benicar (olmesartan) was initially approved by the U.S. Food and Drug Administration (FDA) in 2002, and has since become the most widely-used blood pressure medication in the United States, distributed by Daiichi Sankyo and Forest Laboratories. However, mounting research has identified Benicar use as a potential risk factor for a number of serious side effects, including long-term diarrhea, weight loss, and other symptoms that can lead to severe intestinal damage known as villous atrophy, or death. In July 2013, the FDA issued a drug safety communication warning consumers and medical professionals for the first time about a possible link between Benicar and sprue-like enteropathy – a condition characterized by severe, chronic diarrhea and substantial weight loss.
As more and more Benicar users become aware of the alleged link between use of the popular blood pressure medication and potentially life-threatening side effects like villous atrophy and sprue-like enteropathy, the number of Benicar lawsuits filed in courts throughout the country has continued to grow. The drug injury lawsuits all involve similar allegations that Daiichi Sankyo and Forest Laboratories failed to provide consumers with adequate warnings about the risk of Benicar side effects. As product liability attorneys across the United States continue to investigate potential claims for former Benicar users, estimates suggest that hundreds, or possibly even thousands, of Benicar lawsuits will ultimately be included in the litigation.
